
Contents

Foreword	ix
<i>Beth Shaz and Christopher D. Hillyer</i>	

Introduction	xiii
<i>Paul M. Ness and Christopher D. Hillyer</i>	

DONOR MANAGEMENT

1. How do we design, implement, and manage an ongoing program to provide iron supplements to women blood donors?	1
<i>Linda K. White, Vicki J. Harris, Julie L. Cruz, and Dan A. Waxman</i>	
2. How do I provide leukapheresis products? Blood center experience and evidence for process improvement	9
<i>Yelena Ginzburg, Debra Kessler, Manlio Narici, Melinda Caltabiano, Mark Rebosa, Donna Strauss, and Beth Shaz</i>	
3. How do I investigate septic transfusion reactions and blood donors with culture-positive platelet donations?	17
<i>Anne F. Eder and Mindy Goldman</i>	
4. How do I tell a blood donor that he or she has a positive HIV test?	25
<i>Jorge A. Rios and Thomas M. Koch</i>	

TRANSFUSION SERVICES

5. How do we integrate transfusion medicine and tissue dispensing programs in an academic medical center? Response to a changing regulatory environment	35
<i>Robert W. Maitta, Lonnie Avery, Melanie Champion, Douglas Vaughn, Christopher Baillargeon, Joseph Lederer, and Edward L. Snyder</i>	
6. How do we monitor hospital transfusion practice using an end-to-end electronic transfusion management system?	45
<i>Michael F. Murphy, Edward Fraser, David Miles, Simon Noel, Julie Staves, Barbara Cripps, and Jonathan Kay</i>	
7. How do we approach a major change program using the example of the development, evaluation, and implementation of an electronic transfusion management system?	57
<i>Michael F. Murphy, Julie Staves, Amanda Davies, Edward Fraser, Rachel Parker, Barbara Cripps, Jonathan Kay, and Charles Vincent</i>	
8. How we provide thawed plasma for trauma patients	67
<i>James R. Stubbs, Martin D. Zielinski, Kathleen S. Berns, Karafa S. Badjie, Craig D. Tauscher, Scott A. Hammel, Scott P. Zietlow, and Donald Jenkins</i>	
9. How we manage AB plasma inventory in the blood center and transfusion service	75
<i>Mark Yazer, Anne F. Eder, and Kevin J. Land</i>	

CONTENTS

- 10. How do I allocate blood products at the end of life? An ethical analysis with suggested guidelines** 83
Lauren B. Smith, Laura Cooling, and Robertson Davenport
- 11. How we mitigate risk of ABO-incompatible plasma in plateletpheresis products** 89
Magali J. Fontaine, Anne M. Mills, Susan Weiss, Wan-Jen Hong, Maurene Viele, and Lawrence T. Goodnough
- 12. How do I manage a blood shortage in a transfusion service?** 95
Leo J. McCarthy
- 13. How we manage requests for recombinant factor VIIa** 99
Prasad Mathew, Toby L. Simon, Kristin E. Hunt, and Kendall P. Crookston

TRANSFUSION REACTIONS

- 14. How is national recipient hemovigilance conducted in the United States?** 107
Koo-Whang Chung, Alexis Harvey, Sridhar V. Basavaraju, and Matthew J. Kuehnert
- 15. How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention** 113
Chester Andrzejewski Jr, Mark A. Casey, and Mark A. Popovsky
- 16. How do we prevent transfusion-associated graft-vs-host disease in children?** 125
Karen E. King and Paul M. Ness
- 17. How do we investigate and manage donors associated with a suspected case of transfusion-related acute lung injury?** 131
Leon Su and Hany Kamel
- 18. How I minimize mistransfusion risk in my hospital** 139
James P. AuBuchon
- 19. How I manage patients suspected of having had an IgA anaphylactic transfusion reaction** 145
S. Gerald Sandler

MOLECULAR TESTING

- 20. How do I manage Rh typing in obstetric patients?** 149
Richard L Haspel and Connie M. Westhoff
- 21. How do we use molecular red blood cell antigen typing to supplement pretransfusion testing?** 155
Suneeti Sapatnekar and Priscilla I. Figueroa
- 22. How we incorporate molecular typing of donors and patients into our hospital transfusion service** 163
Hedyeh Shafi, Ihab Abumuhor, and Ellen Klapper
- 23. How do we identify RHD variants using a practical molecular approach?** 171
Carine Prisco Arnoni, Flavia Roche Moreira Latini, Janaina Guilhem Muniz, Diana Gazito, Rosangela de Medeiros Person, Tatiane Aparecida de Paula Vendrame, Jose Augusto Barreto, and Lilian Castilho

PATIENT BLOOD MANAGEMENT

24. **How do we utilize a transfusion safety officer?** 179
Nancy M. Dunbar and Zbigniew M. Szczepiorkowski
25. **How do I implement a more restrictive transfusion trigger of hemoglobin level 7 g/dL at my hospital?** 185
Leonard I. Boral, Andrew Bernard, Todd Hjorth, Daniel Davenport, Daoping Zhang, and Duncan C. MacIvor
26. **How would I establish a perioperative blood salvage program?** 195
Mary Berg and George Justison
27. **How do we integrate thromboelastography with perioperative transfusion management?** 201
Duncan C. MacIvor, Annette Rebel, and Zaki-Udin Hassan
28. **How do I audit hospital blood product utilization?** 209
Richard L. Haspel and Lynne Uhl
29. **How we closed the gap between red blood cell utilization and whole blood collections in our institution** 213
Maris B. Marques, Sherry R. Polhill, Michael R. Waldrum, James E. Johnson, Joseph Timpa, Anthony Patterson, and Donna Salzman
30. **How do I implement a hospital-based blood management program?** 225
Mark H. Yazer and Jonathan H. Waters

SPECIFIC PATIENT MANAGEMENT

31. **How do we treat life-threatening anemia in a Jehovah's Witness patient?** 231
Joseph A. Posluszny Jr and Lena M. Napolitano
32. **How do we approach the patient who refuses blood transfusion?** 241
David M. Rogers and Kendall P. Crookston
33. **How do we manage cardiopulmonary bypass coagulopathy?** 249
Kerry J. Welsh, Elena Nedelcu, Yu Bai, Amer Wahed, Kimberly Klein, Hlaing Tint, Igor Gregoric, Manish Patel, Biswajit Kar, Pranav Loyalka, Sriram Nathan, Paul Loubser, Phillip A. Weeks, Rajko Radovancevic, and Andy N.D. Nguyen
34. **How we use WinRho in patients with idiopathic thrombocytopenic purpura** 259
Brie A. Stotler and Joseph Schwartz
35. **How do I transfuse platelets to reverse antiplatelet drug effect?** 263
Ravi Sarode
36. **How do we manage patients treated with antithrombotic therapy in the perioperative interval?** 271
Arthur W. Bracey, Meredith A. Reyes, Alice J. Chen, Maryam Bayat, and Paul M. Allison
37. **How can we select platelet products for alloimmune-refractory patients?** 283
Patricia M. Kopko, Paul Warner, Lesley Kresie, and Carol Pancoska
38. **How I do it: platelet support for refractory patients** 293
Sunny Dzik
39. **How do I transfuse patients with sickle cell disease** 299
Keith Quirolo

CONTENTS

40. **How do I approach patients with warm-reactive autoantibodies?** 305
Douglas P. Blackall
41. **How we evaluate panagglutinating sera** 309
Jacques Chiaroni, Julia Gouvitsos, Isabelle Dettori, and Virginie Ferrera
42. **How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations?** 315
Paul M. Ness
43. **How I manage cold agglutinins** 319
W. John Judd
44. **How we provide transfusion medicine support for obstetric services** 323
Lawrence T. Goodnough, Kay Daniels, Amy E. Wong, Maurene Viele, Magali F. Fontaine, and Alexander J. Butwick
45. **How we manage life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol** 333
Matthew Burtelow, Ed Riley, Maurice Druzin, Magali Fontaine, Maurene Viele, and Lawrence T. Goodnough
46. **How do we provide blood products to trauma patients?** 343
Shan Yuan, Alyssa Ziman, Mary Anne Anthony, Elsa Tsukahara, Courtney Hopkins, Qun Lu, and Dennis Goldfinger

NEONATES/ PEDIATRICS

47. **How do we treat fetal and neonatal alloimmune thrombocytopenia?** 349
Gérald Bertrand and Cécile Kaplan
48. **How we provide transfusion support for neonatal and pediatric patients on extracorporeal membrane oxygenation** 355
Shan Yuan, Elsa Tsukahara, Kim De La Cruz, and Robert B. Kelly
49. **How do we teach pediatric topics in transfusion medicine? Curriculum development, learners, and instructional strategies** 365
Daniel R. Ambruso, Rosa Sanchez, Steven R. Sloan, Cassandra D. Josephson, and the Pediatric TMAA Group
50. **How do we improve platelet transfusion practices in the neonatal intensive care unit?** 373
Robert D. Christensen, David A. Paul, Martha Sola-Visner, and Vickie L. Baer
51. **How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity** 377
Ronald G. Strauss

APHERESIS SERVICES

52. **How do we approach a patient with symptoms of leukostasis requiring emergent leukocytapheresis?** 387
Huy P. Pham and Joseph Schwartz
53. **How we developed and use the American Society for Apheresis guidelines for therapeutic apheresis procedures** 393
Beth H. Shaz, Joseph Schwartz, and Jeffrey L. Winters

-
- 54. How we approach an apheresis request for a Category III, Category IV, or noncategorized indication** 403
Beth H. Shaz, Jeffrey L. Winters, Nicholas Bandarenko, and Zbigniew M. Szczepiorkowski
- 55. How we approach an acquired thrombotic thrombocytopenic purpura patient** 413
Jay S. Raval, Marshall A. Mazepa, Mark E. Brecher, and Yara A. Park
- 56. How I approach a thrombotic thrombocytopenia purpura patient** 421
Mark E. Brecher

CELLULAR THERAPY

- 57. How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions** 425
Ronit Reich-Slotky, Lohith S. Bachegowda, Michael Ancharski, Lyubov Mendeleyeva, Pablo Rubenstein, Hanna Rennert, Tsiporah Shore, Koen van Besien, and Melissa Cushing
- 58. How do I approach ABO-incompatible hematopoietic progenitor cell transplantation?** 433
Jennifer Daniel-Johnson and Joseph Schwartz